Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: We are but a few

Under SEC Rule 14a-8 the proposal was for nomination to the BoD which made it clearly ineligible:

http://taft.law.uc.edu/CCL/34ActRls/rule14a-8.html

Rule 14a-8(i)(8) is one of the thirteen substantive bases upon which a company may rely to exclude a shareholder proposal from its proxy materials. The agency's longstanding interpretation of Rule 14a-8(i)(8) - commonly known as the election exclusion - permits a company to omit from its proxy materials any shareholder proposal that would result in an immediate election contest or would set up a process for shareholders to conduct an election contest in the future by requiring the company to include shareholders' director nominees in the company's proxy materials for subsequent meetings

http://www.sec.gov/info/smallbus/secg/rule14a-8i8-secg.htm

No idea about Schrock and Mistry, perhaps you could try contacting them directly as your interests are clearly aroused?

.

.

.

Be well

Share
New Message
Please login to post a reply